Ropivacaine hydrochloride monohydrate (Synonyms: LEA 103, (S)-Ropivacaine) |
| カタログ番号GC16390 |
ロピバカイン塩酸塩一水和物は、強力なナトリウムチャネルブロッカーであり、神経線維におけるナトリウムイオン流入の可逆的阻害を介してインパルス伝導をブロックします。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 132112-35-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ropivacaine hydrochloride monohydrate is an effective, long-acting and local anaesthetic [1].
In COS-7 cells, Ropivacaine hydrochloride monohydrate has been reported to inhibit the the SUR2A/Kir6.2 channel currents. The inhibitory effects of Ropivacaine have shown be concentration-dependent and reversible because the channel currents recovered after washout. Furthermore, the IC50 values of Ropivacaine hydrochloride monohydrate are 249±11, 2235±115, 2442±132 and 2375±179μM for SUR2A/Kir6.2, SUR2B/Kir6.1, SUR2B/Kir6.2 and Kir6.2△C36, respectively. Apart from these, Ropivacaine hydrochloride monohydrate has also demonstrated to inhibit sarcolemmal KATP channels in the cardiovascular system by a stereoselective and tissue-specific way[2].
References:
[1] Reiz S1, Häggmark S, Johansson G, Nath S. Cardiotoxicity of ropivacaine--a new amide local anaesthetic agent. Acta Anaesthesiol Scand. 1989 Feb;33(2):93-8.
[2] Kawano T1, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y. Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Anesthesiology. 2004 Aug;101(2):390-8.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *